Applicant: Akira Hayasaka et al. Attorney's Docket No.: 14875-0158US1 / C1-A0319-P US

Serial No.: 10/574,827 Filed: March 27, 2007

Page : 2 of 9

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

<u>Listing of Claims</u>:

1. (Currently amended) A method for stabilizing an IgM-suppressing cryoprecipitation of IgM in a solution at a temperature of 1°C to 7°C, wherein the method comprises adding a citric acid buffer to a first solution comprising the IgM to form a second solution comprising the IgM at a concentration of 20 mg/ml or greater, and maintaining the second solution at 1°C to 7°C, thereby suppressing cryoprecipitation of stabilizing the IgM.

2-3. (Canceled)

- 4. (Previously presented) The method of claim 1, wherein the pH of the second solution is 5 to 8.
- 5. (Previously presented) The method of claim 1, comprising cooling the second solution to a temperature of $7 \, ^{\circ}$ C.
- 6. (Previously presented) The method of claim 1, comprising cooling the second solution to a temperature of 4 $^{\circ}$ C.
- 7. (Previously presented) The method of claim 1, comprising cooling the second solution to a temperature of 1 $^{\circ}$ C.
- 8. (Previously presented) The method of claim 1, wherein the concentration of citric acid buffer in the second solution is 1 mM to 500 mM.

Applicant: Akira Hayasaka et al. Attorney's Docket No.: 14875-0158US1 / C1-A0319-P US

Serial No.: 10/574,827 Filed: March 27, 2007

Page : 3 of 9

9. (Previously presented) The method of claim 8, wherein the concentration of citric acid buffer in the second solution is 5 mM to 100 mM.

- 10. (Previously presented) The method of claim 9, wherein the concentration of citric acid buffer in the second solution is 10 mM to 50 mM.
 - 11. (Previously presented) The method of claim 1, wherein the IgM is purified.
- 12. (Previously presented) The method of claim 1, comprising cooling the second solution to a temperature between 1 °C and 7 °C.
- 13. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 1 $^{\circ}$ C.
- 14. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 4 $^{\circ}$ C.
- 15. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 7 $^{\circ}$ C.
 - 16. (New) The method of claim 4, wherein the pH of the second solution is 5 to 6.
- 17. (New) The method of claim 1, wherein the concentration of the IgM in the second solution is 25 mg/ml or greater.
- 18. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 30% or more, expressed as a cryoprecipitation increase suppression rate.

Applicant: Akira Hayasaka et al. Attorney's Docket No.: 14875-0158US1 / C1-A0319-P US

Serial No.: 10/574,827 Filed: March 27, 2007

Page : 4 of 9

19. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 50% or more, expressed as a cryoprecipitation increase suppression rate.

20. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 80% or more, expressed as a cryoprecipitation increase suppression rate.